Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment - PubMed (original) (raw)
Clinical Trial
. 1999 Oct 6;282(13):1240-6.
doi: 10.1001/jama.282.13.1240.
Affiliations
- PMID: 10517426
- DOI: 10.1001/jama.282.13.1240
Clinical Trial
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment
F G Hayden et al. JAMA. 1999.
Abstract
Context: Influenza virus neuraminidase is thought to be essential for virus replication in humans; however, to date, available neuraminidase inhibitors are limited to zanamivir, which is topically administered.
Objective: To determine the safety, tolerability, and antiviral activity of oral neuraminidase inhibitor oseltamivir (GS4104/Ro64-0796) for prevention and the early treatment of influenza in experimentally infected humans.
Design: Two randomized, double-blind, placebo-controlled trials conducted between June and July 1997.
Setting: Individual hotel rooms; 2 large US university medical schools.
Participants: A total of 117 healthy adult volunteers (aged 18-40 years; median age, 21 years) who were susceptible (hemagglutination-inhibition antibody titer < or =1:8).
Interventions: All subjects were inoculated intranasally with influenza A/Texas/36/91 (H1N1) virus. For the prophylaxis study, oral oseltamivir (100 mg once daily [n = 12], 100 mg twice daily [n = 12], or matching placebo [n = 13], starting 26 hours before virus inoculation) was administered. For the treatment study, the same drug was given (20 mg, 100 mg, or 200 mg twice daily, 200 mg once daily, or matching placebo [n = 16], in each group starting 28 hours after inoculation). All regimens were continued for 5 days.
Main outcome measures: Comparing placebo groups with pooled treatment groups, for prophylaxis, outcomes included frequency of infection and viral shedding; for treatment, viral shedding in titers.
Results: In the prophylaxis study, 8 (67%) of 12 placebo and 8 (38%) of 21 oseltamivir recipients became infected (P = .16; efficacy, 61%); 6 (50%) placebo compared with 0 oseltamivir recipients shed virus (P<.001; efficacy, 100%), and 33% of placebo but no oseltamivir recipient had infection-related respiratory illness (P<.01). Among infected subjects in the treatment study (n = 69), the viral titer area under the curve of the combined oseltamivir groups (n = 56) was lower (median [interquartile range [IQR]], 80 [23-151] vs 273 [79-306] log10 tissue culture-infective doses50 per milliliter x hour; P = .02) than the placebo group (n = 13), and the median (IQR) duration of viral shedding with therapy was reduced from 107 (83-131) to 58 (35-59) hours (P = .003). Oseltamivir treatment also reduced symptom scores (median [IQR] score-hours, 225 [97-349] vs 400 [189-645]; P = .05), and nasal proinflammatory cytokine levels. Transient mild to moderate nausea after dosing was observed in 15 (17%) of 88 oseltamivir and 2 (7%) of 29 placebo recipients (95% confidence interval for difference, -11% to 68%), which was largely prevented by ingestion with food.
Conclusions: In these trials, prophylaxis and early treatment with oral oseltamivir were both associated with significant antiviral and clinical effects in experimental human influenza.
Similar articles
- Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza.
Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Hayden FG, et al. N Engl J Med. 1999 Oct 28;341(18):1336-43. doi: 10.1056/NEJM199910283411802. N Engl J Med. 1999. PMID: 10536125 Clinical Trial. - Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
Treanor JJ, Hayden FG, Vrooman PS, Barbarash R, Bettis R, Riff D, Singh S, Kinnersley N, Ward P, Mills RG. Treanor JJ, et al. JAMA. 2000 Feb 23;283(8):1016-24. doi: 10.1001/jama.283.8.1016. JAMA. 2000. PMID: 10697061 Clinical Trial. - Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza.
Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Hayden FG, et al. JAMA. 1996 Jan 24-31;275(4):295-9. JAMA. 1996. PMID: 8544269 Clinical Trial. - Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. Jefferson T, et al. Cochrane Database Syst Rev. 2014 Apr 10;2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4. Cochrane Database Syst Rev. 2014. PMID: 24718923 Free PMC article. Review. - Oseltamivir: a review of its use in influenza.
McClellan K, Perry CM. McClellan K, et al. Drugs. 2001;61(2):263-83. doi: 10.2165/00003495-200161020-00011. Drugs. 2001. PMID: 11270942 Review.
Cited by
- Evaluation of Vaccine Immunogenicity-Correlates to Real-World Protection: Influenza.
Laszlofy C, Fazekas G, Barath Z, Vajo Z. Laszlofy C, et al. Viruses. 2024 Mar 12;16(3):441. doi: 10.3390/v16030441. Viruses. 2024. PMID: 38543806 Free PMC article. Review. - The role of sialidases in the pathogenesis of bacterial vaginosis and their use as a promising pharmacological target in bacterial vaginosis.
Chen L, Li J, Xiao B. Chen L, et al. Front Cell Infect Microbiol. 2024 Mar 1;14:1367233. doi: 10.3389/fcimb.2024.1367233. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38495652 Free PMC article. Review. - The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study.
Aljuhani O, Korayem GB, Altebainawi AF, Alotaibi MS, Alrakban NA, Ghoneim RH, Vishwakarma R, Al Shaya AI, Al Harbi S, Gramish J, Almutairi DM, Alqannam G, Alamri FF, Alharthi AF, Alfaifi M, Al Amer A, Alenazi AA, Bin Aydan N, Alalawi M, Al Sulaiman K. Aljuhani O, et al. Saudi Pharm J. 2023 Jul;31(7):1210-1218. doi: 10.1016/j.jsps.2023.05.006. Epub 2023 May 23. Saudi Pharm J. 2023. PMID: 37256102 Free PMC article. - Co-infection of the respiratory epithelium, scene of complex functional interactions between viral, bacterial, and human neuraminidases.
Escuret V, Terrier O. Escuret V, et al. Front Microbiol. 2023 May 4;14:1137336. doi: 10.3389/fmicb.2023.1137336. eCollection 2023. Front Microbiol. 2023. PMID: 37213507 Free PMC article. Review. - Influenza antivirals and their role in pandemic preparedness.
Jones JC, Yen HL, Adams P, Armstrong K, Govorkova EA. Jones JC, et al. Antiviral Res. 2023 Feb;210:105499. doi: 10.1016/j.antiviral.2022.105499. Epub 2022 Dec 23. Antiviral Res. 2023. PMID: 36567025 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical